Dr. Dirk Waldenmaier
About Dr. Dirk Waldenmaier
Dr. Dirk Waldenmaier is the Medical Director Hematology, Myeloid at Bristol Myers Squibb, with over two decades of experience in the medical and pharmaceutical industries, particularly in hematology and oncology.
Title
Dr. Dirk Waldenmaier serves as the Medical Director Hematology, Myeloid at Bristol Myers Squibb.
Current Role at Bristol Myers Squibb
Dr. Dirk Waldenmaier is currently employed as the Medical Director of Hematology, Myeloid at Bristol Myers Squibb. In this capacity, he is responsible for overseeing medical protocols and strategies related to hematologic malignancies with a particular focus on myeloid diseases.
Previous Positions at Celgene
Before his role at Bristol Myers Squibb, Dr. Dirk Waldenmaier held various significant positions at Celgene. He started as a Regional Medical Liaison in Hematology from 2012 to 2016 in the Munich area. He then progressed to Associate Director Medical Affairs - Hematology, before transitioning to Associate Director Medical Affairs - Myeloid Diseases & Oncology from 2019 to 2020. His final position at Celgene was Associate Medical Director Hematology, Myeloid in 2021.
Experience in Medical Affairs
Dr. Dirk Waldenmaier has an extensive background in medical affairs, with a focus on hematology and oncology. His roles have included Associate Medical Director, Associate Director Medical Affairs, and Regional Medical Liaison, primarily working in the Munich area. He has consistently engaged in roles that bridge clinical research and medical strategy.
Educational Background
Dr. Dirk Waldenmaier studied at Ludwig-Maximilians-Universität München, where he specialized in oncologic diagnostics and earned a Dr. rer. nat. He also attended The University of Freiburg, where he studied Biology and Economy, obtaining a Dipl. Biol. His academic background supports his interdisciplinary approach in the medical field.